SecBot SecBot
SECBOTREPLAY Home › Report › FRNM

FRNM · Q3 rev $183.5M, FDA milestone

Freenome, LLC · PRESS-RELEASE filed Nov 10, 2026 at 16:01 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Nov 10, 2026 at 16:01 ET

Freenome reported Q3 2026 total revenue of $183.5M, far above the $84.9M consensus, driven by a $100M milestone payment from Abbott following FDA approval of SimpleScreen CRC. GAAP net income swung to $60.1M from a loss of $64.5M a year ago. The company guided full-year 2026 revenue to $192M-$194M.

  • Total revenue $183.5M vs consensus $84.9M, driven by $182.5M in license and collaboration revenue including a $100M milestone from Abbott
  • GAAP net income $60.1M vs net loss of $64.5M in Q3 2025
  • Adjusted EBITDA $117.9M vs negative $56.3M in Q3 2025
  • Cash and marketable securities $430.0M as of September 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access